Bayer to shed Material Science unit via IPO
This article was originally published in Scrip
Bayer is spinning off its Material Science unit and will float it on the stock markets as a separate company so it can focus entirely on its two Life Science businesses – Health Care and Crop Science. The decision follows recent similar moves by its pharma peers to shed non-core businesses.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.